NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$3.59
+0.03 (+0.84%)
(As of 01:48 PM ET)
Today's Range
$3.44
$3.74
50-Day Range
$3.56
$4.63
52-Week Range
$3.44
$6.29
Volume
10,845 shs
Average Volume
84,140 shs
Market Capitalization
$155.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.18
Upright™ Environmental Score
News Sentiment
0.14mentions of Harvard Bioscience in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.58 out of 5 stars

Computer And Technology Sector

351st out of 591 stocks

Analytical Instruments Industry

16th out of 26 stocks

HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

Jim Cramer’s “The Biggest Drug Ever”
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Jim Cramer’s “The Biggest Drug Ever”
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Harvard man pleads guilty to assault
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/26/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
391
Year Founded
1901

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-2.28%

Debt

Sales & Book Value

Annual Sales
$112.25 million
Cash Flow
$0.22 per share
Book Value
$1.71 per share

Miscellaneous

Free Float
39,493,000
Market Cap
$154.50 million
Optionable
Optionable
Beta
1.42

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

HBIO Stock Analysis - Frequently Asked Questions

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 at the beginning of the year. Since then, HBIO shares have decreased by 33.1% and is now trading at $3.58.
View the best growth stocks for 2024 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest in April. As of April 15th, there was short interest totaling 673,000 shares, an increase of 5.7% from the March 31st total of 636,700 shares. Based on an average trading volume of 86,900 shares, the short-interest ratio is presently 7.7 days.
View Harvard Bioscience's Short Interest
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its earnings results on Thursday, March, 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $28.15 million during the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive trailing twelve-month return on equity of 2.75%.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Triton Wealth Management PLLC (0.03%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners